Maintenance Cediranib in Ovarian Cancer Fails to Show Significant OS Improvement

Despite previously reported progression-free survival improvements with cediranib, results from the ICON6 trial failed to show a statistically significant improvement in overall survival. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rxoSEk
via IFTTT